P.2.c.034 Prefrontal metabolic abnormalities in major depressive disorder: a proton magnetic resonance spectroscopy study

Abstract

Methamphetamine (MA) use has been shown to decrease n-acetyl-aspartate (NAA), a marker of neuronal integrity and viability, on 1H magnetic resonance spectroscopy (1H-MRS). However, little work has compared 1H-MRS in MA dependent individuals and MA dependent individuals with MA induced psychotic disorder (MAP).Twenty six participants with MA dependence (sixteen without psychosis, ten with psychosis — MAP) and nineteen healthy controls underwent 2D-chemical shift imaging 1H-MRS, which included voxels in the anterior cingulate cortices (ACC), dorsolateral prefrontal cortices (DLPFC), and frontal white matter. We compared metabolite concentrations relative to phosphocreatine + creatine (PCr + Cr) for n-acetyl-aspartate (NAA), n-acetyl-aspartate + n-acetyl-aspartyl-glutamate (NAA + NAAG), glutamate (Glu), glutamate + glutamine (Glu + Gln), myo-inositol, and glycerophosphocholine + phosphocholine (GPC + PCh) across groups.The MA groups showed significantly decreased relative NAA metabolite concentrations for right ACC and right DLPFC, compared with control group. The MA dependent group only showed significantly decreased choline metabolites for right DLPFC, compared with control group. The MAP group's relative NAA metabolite concentrations were significantly correlated with age of initial use and duration of MA use, these correlates were not apparent in MA dependent group.MA use is associated with decreased neuronal integrity and viability, specifically in the right ACC and right DLPFC. MA dependence showed active neurodegeneration in the right DLPFC, this was not apparent in the MAP group and may be related to the use of antipsychotic medication in the MAP group. The effects of MA use in MAP suggest that age of initial use presents a mismatch of neuronal plasticity, in frontal white vs. gray matter and duration of use relates to decreased neuronal integrity and viability. Further study is warranted from this initial study of 1H-MRS in MAP, in particular longitudinal assessment of these individuals both neurobiologically (1H-MRS) and clinically — to determine disease progression.